Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telitacicept versus placebo in moderate to severe active systemic lupus erythematosus
CTR20232612Phase 3Active
- Sponsor
- RemeGen
- Start
- Nov 2023
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of telitacicept in systemic lupus erythematosus (SLE), sponsored by RemeGen. Started Nov 2023; status: active.
02
Drugs
telitacicept
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on CTR20232612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232612.